How to contact the center
Full member
HCP Center
CHUC's mission is to provide high quality and differentiated health care in a context of training, teaching, research, scientific knowledge and innovation, constituting itself as a national and international reference in areas considered as poles of excellence.
CHUC is an open organization formed by a network of hospitals, services and technologies structured and integrated to provide a humanized, complete, close, reliable and transparent service to society. It is a center distinguished by the quality of care, research capacity, innovation and teaching and by the positive impact on the community, ensuring efficiency and global sustainability in the medium and long term.
Values and Principles
a) Public service with primacy in the patient.
b) Respect for human dignity, cultural and religious diversity and the rights of the sick;
c) Universality of access to health care and treatment equity;
d) Rigor, integrity and responsibility;
e) High standards of humanization, quality and technical and scientific competence of the services provided;
f) team spirit;
g) Respect for the values of a just, solidary, humanistic and personalistic society;
h) Respect for the culture and founding traditions of the pioneering hospitals, assuming the duty to add something to the inherited culture capital, with a view to developing the collective culture of the new institution;
i) Social responsibility
Picture : Alvesgaspar
CHUC is an open organization formed by a network of hospitals, services and technologies structured and integrated to provide a humanized, complete, close, reliable and transparent service to society. It is a center distinguished by the quality of care, research capacity, innovation and teaching and by the positive impact on the community, ensuring efficiency and global sustainability in the medium and long term.
Values and Principles
a) Public service with primacy in the patient.
b) Respect for human dignity, cultural and religious diversity and the rights of the sick;
c) Universality of access to health care and treatment equity;
d) Rigor, integrity and responsibility;
e) High standards of humanization, quality and technical and scientific competence of the services provided;
f) team spirit;
g) Respect for the values of a just, solidary, humanistic and personalistic society;
h) Respect for the culture and founding traditions of the pioneering hospitals, assuming the duty to add something to the inherited culture capital, with a view to developing the collective culture of the new institution;
i) Social responsibility
Picture : Alvesgaspar
Contact
Centro Hospitalar e Universitário de Coimbra – CHUC, Coimbra, Portugal
Praceta Professor Mota Pinto
3004-561 Coimbra
Portugal
Team
Prof Joaquim Murta
Representative
Portugal
Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8)
Dr João Pedro Marques
Substitute
Portugal
National Integration (TWG9), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Dr Jorge Henriques
Portugal
Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), National Integration (TWG9), Research (TWG8)
Dr Raimundo Miguel
Portugal
Anterior Segment Rare Eye Diseases (WG4), Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8)
Dr Catarina Paiva
Portugal
Low Vision Daily Life and Patients Groups (TWG5), Pediatric Ophthalmology Rare Diseases (WG3)
Joao Quadrado Gil
Portugal
Anterior Segment Rare Eye Diseases (WG4), Registries & Epidemiology (TWG7), Research (TWG8)
Pr Rufino Silva
Portugal
Genetic Diagnostics (TWG6), National Integration (TWG9), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Clinical trials
NCT03584243 - Unknown
Transepithelial Corneal Collagen Crosslinking in Eyes With Progressive Keratoconus.
Interventional
NCT04423718 - Active, Not recruiting
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Interventional
NCT05642312 - Recruiting, Active
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema
Interventional